(Q38052066)

27 August 2017

title

Use of omalizumab in the treatment of food allergy and anaphylaxis (English)

1 reference

27 August 2017

1 reference

1 reference

Jay A Lieberman

1

1 reference

27 August 2017

Mirna Chehade

series ordinal

2

1 reference

27 August 2017

publication date

1 February 2013

1 reference

Current Allergy and Asthma Reports

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

78-84

1 reference

https://scigraph.springernature.com/pub.10.1007/s11882-012-0316-x

27 August 2017

exact match

0 references

cites work

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Effect of anti-IgE therapy in patients with peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Oral immunotherapy for treatment of egg allergy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Anti-IgE treatment of eosinophil-associated gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab in the treatment of eosinophilic esophagitis and food allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Idiopathic anaphylaxis successfully treated with omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab in idiopathic anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Promising option in the prevention of idiopathic anaphylaxis: omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Successful treatment of idiopathic anaphylaxis in an adolescent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Successful use of omalizumab for prevention of fire ant anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-012-0316-X

Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization

21 January 2018

1 reference

12 December 2020

Omalizumab treatment of systemic mast cell activation disease: experiences from four cases

1 reference

12 December 2020

Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis

1 reference

12 December 2020

1 reference

12 December 2020

Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.

1 reference

12 December 2020

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

1 reference

12 December 2020

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

1 reference

12 December 2020

Successful treatment of exercise-induced anaphylaxis with omalizumab

1 reference

12 December 2020

Serum IgE level drives basophil and mast cell IgE receptor display

1 reference

12 December 2020

10.1007/S11882-012-0316-X

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1026742717

0 references

1 reference